Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
BCBioAtla, Inc. logo

BioAtla, Inc. (BCAB)

NASDAQ Global Market · Currency in USD
$1.74 ▲ +0.42 (+31.44%)
At close: Aug 28, 4:00 PM ET. Market closed.
$1.76 ▲ +0.02 (+1.44%)
After hours: Aug 28, 7:59 PM ET

Summary

Previous Close
$1.32
Open
$1.58
Day's Range
$1.58 – $2.06
52 Week Range
$1.07 – $71.50
Volume
1,031,528
Avg. Volume
65,625
Market Cap
$2.88M
Beta (5Y Monthly)
0.76
PE Ratio (TTM)
--
EPS (TTM)
-$18.94
Earnings Date
Nov 12, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$250.00

Profile: BioAtla, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
41
CEO
Jay Short

BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer. Additionally, BioAtla is advancing BA3021, another CAB ADC, for a variety of solid malignancies such as NSCLC, melanoma, and ovarian cancer.

Earnings

Next report: Thu, Nov 12, 2026
EPS estimate -$7.00 · Revenue est. $5.59M
DateEst.Actual
Aug 13, 2026-$8.50$0.27Beat
May 15, 2026-$10.00-$6.18Beat
Mar 31, 2026-$12.00-$8.00Beat
Nov 13, 2025-$0.31-$13.50Miss
Aug 7, 2025-$0.29-$16.00Miss
May 6, 2025-$0.29-$13.00Miss

Analyst view

Consensus price target
$250.00 ▲ +14,309.2%
Range $250.00 – $250.00
Rating: Buy
Buy 67% · Hold 33% · Sell 0%

Get free alerts on BCAB and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.